Pelvic inflammatory disease (PID) is an infection of the female upper genital tract that is
typically polymicrobial with classic core involvement of Neisseria gonorrhoeae and/or …

Introduction Single-dose 2-g oral secnidazole (SEC), newly approved by the US Food and
Drug administration (FDA) for treatment of trichomoniasis, is a potent 5-nitroimidazole with …

Trichomonas vaginalis is a parasitic protist that infects the human urogenital tract. During the
infection, trichomonads adhere to the host mucosa, acquire nutrients from the …

Approaches for effective and sustained drug delivery to the female reproductive tract (FRT)
for treating a range of gynaecological conditions remain limited. The development of …

ABSTRACT Introduction Secnidazole (SEC), newly FDA-approved for trichomoniasis, is a
potent 5-nitroimidazole with selective toxicity against various infections. It has been used …

Background. Antimicrobial resistance poses a significant global threat to the treatment of
bacterial infections, particularly in low‐and middle‐income regions such as Africa. This study …

Trichomonas vaginalis is a pathogenic protozoan diffused worldwide capable of infecting
the urogenital tract in humans, causing trichomoniasis. One of its most intriguing aspects is …

Background Differences in opinion concerning the contribution of M. genitalium to pelvic
inflammatory disease (PID) has resulted in inconsistencies across global testing and …

Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection (STI)
worldwide, 1 affecting~ 3.7 million individuals in the United States. 2 The prevalence is …

We describe a case of persistent 5-nitroimidazole–resistant trichomoniasis cured after 14
days of oral secnidazole and intravaginal boric acid. Secnidazole may be an important …